Ajanta Pharma Ltd.

NSE: AJANTPHARM | BSE: 532331 | ISIN: INE031B01049 | Industry: Pharmaceuticals
| Mid-range Performer
2636.3000 -58.90 (-2.19%)
NSE Aug 04, 2025 15:31 PM
Volume: 111.9K
 

logo
Ajanta Pharma Ltd.
20 Dec 2017
2636.30
-2.19%
Motilal Oswal
Inventory has been gradually restoring post GST roll-out from very low levels,and the streamlining of supply-side system is leading to sustained better off-take in domestic formulation (DF). A JP is building a facility at Guwahati to reduce outsourcing, and thus, ensure better administrative control/compliance and also enjoy tax benefits. Although only five ANDAs were filed for the US market in 1HFY18, the company has maintained its guidance of 10-15 filings over FY18. After declining sharply in 2QFY18, US sales are expected to pick up, l ed by the launch of recently approved products and increased traction in existing products.AJP has been selected as a supplier in the institutional anti-malaria business from the Global Fund, but is yet to obtain orders. The company maintained its guidance of 15-20 % YoY lower sales in FY18 due to lower allocation from the Global Fund.
Ajanta Pharma Ltd. is trading below its 30 day SMA of 2676.2
More from Ajanta Pharma Ltd.
Recommended